Charles Pitman CFA
Stock Analyst at Barclays
(4.72)
# 676
Out of 4,486 analysts
364
Total ratings
70.4%
Success rate
16.8%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €50.00 | $51.18 | -2.31% | 16 | Jun 26, 2026 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | $142.80 | -5.46% | 19 | Jun 26, 2026 | |
| EPA: BIM bioMérieux S.A. | Maintained: Hold | €90.00 → €80.00 | $69.55 | +15.03% | 6 | Jun 23, 2026 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 670.00 | $580.40 | +15.44% | 30 | Jun 22, 2026 | |
| SWX: PPGN PolyPeptide Group AG | Maintained: Buy | CHF 33.00 → CHF 40.00 | $49.35 | -18.95% | 6 | Jun 16, 2026 | |
| LON: 0NZT UCB SA | Downgraded: Hold | €310.00 → €300.00 | $260.20 | +15.30% | 131 | Jun 12, 2026 | |
| SWX: BANB Bachem Holding AG | Maintained: Hold | CHF 65.00 → CHF 70.00 | $77.00 | -9.09% | 12 | Jun 9, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Maintained: Buy | €270.00 | $229.90 | +17.44% | 22 | Apr 23, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Maintained: Buy | €220.00 | $179.40 | +22.63% | 17 | Apr 23, 2026 | |
| BME: GRF Grifols, S.A. | Maintained: Buy | €13.50 → €12.50 | $9.06 | +37.91% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 75.00 | $70.64 | +6.17% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €48.00 | $51.45 | -6.71% | 15 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $14.55 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $458.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €105.00 → €60.00 | $70.16 | -14.48% | 3 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €700.00 → €850.00 | $811.30 | +4.77% | 26 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 → €125.00 | $169.50 | -26.25% | 30 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $664 → $744 | $916.80 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $21 | $7.17 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $254.76 | n/a | 1 | Jan 13, 2022 |
Bayer Aktiengesellschaft
Jun 26, 2026
Maintained: Buy
Price Target: €50.00
Current: $51.18
Upside: -2.31%
Merck KGaA
Jun 26, 2026
Maintained: Hold
Price Target: €130.00 → €135.00
Current: $142.80
Upside: -5.46%
bioMérieux S.A.
Jun 23, 2026
Maintained: Hold
Price Target: €90.00 → €80.00
Current: $69.55
Upside: +15.03%
Lonza Group AG
Jun 22, 2026
Maintained: Buy
Price Target: CHF 670.00
Current: $580.40
Upside: +15.44%
PolyPeptide Group AG
Jun 16, 2026
Maintained: Buy
Price Target: CHF 33.00 → CHF 40.00
Current: $49.35
Upside: -18.95%
UCB SA
Jun 12, 2026
Downgraded: Hold
Price Target: €310.00 → €300.00
Current: $260.20
Upside: +15.30%
Bachem Holding AG
Jun 9, 2026
Maintained: Hold
Price Target: CHF 65.00 → CHF 70.00
Current: $77.00
Upside: -9.09%
Sartorius Aktiengesellschaft
Apr 23, 2026
Maintained: Buy
Price Target: €270.00
Current: $229.90
Upside: +17.44%
Sartorius Stedim Biotech S.A.
Apr 23, 2026
Maintained: Buy
Price Target: €220.00
Current: $179.40
Upside: +22.63%
Grifols, S.A.
Apr 22, 2026
Maintained: Buy
Price Target: €13.50 → €12.50
Current: $9.06
Upside: +37.91%
Mar 11, 2026
Maintained: Hold
Price Target: CHF 75.00
Current: $70.64
Upside: +6.17%
Feb 12, 2026
Upgraded: Hold
Price Target: €48.00
Current: $51.45
Upside: -6.71%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $14.55
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $458.00
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: €105.00 → €60.00
Current: $70.16
Upside: -14.48%
Oct 31, 2025
Maintained: Buy
Price Target: €700.00 → €850.00
Current: $811.30
Upside: +4.77%
Oct 24, 2025
Maintained: Hold
Price Target: €120.00 → €125.00
Current: $169.50
Upside: -26.25%
Apr 28, 2025
Maintained: Buy
Price Target: $664 → $744
Current: $916.80
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $21
Current: $7.17
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $254.76
Upside: n/a